

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated:

4-21-05

Signature:



(Rhea Amid)

PATENT
Docket No. 271212000200

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Jens Peter GØTZE et al.

Serial No.: 10/510,880

Filing Date (Int'l): April 11, 2003

For: METHODS FOR DETERMINING
LEVELS OF HUMAN B-TYPE
NATRIURETIC PEPTIDE
PRECURSORS

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

The document numbers 1, 2, 3, 4, 5, 8, 10, and 25 listed on the attached Form PTO/SB/08a/b were cited in an International Search Report mailed on June 25, 2003 (copy attached) directed to a counterpart international or foreign application.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of __ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling;
or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **271212000200**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: April 21, 2005

Respectfully submitted,

By 

Gregory P. Einhorn

Registration No.: 38,440

MORRISON & FOERSTER LLP

3811 Valley Centre Drive

Suite 500

San Diego, California 92130-2332

(858) 720-5133

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/510,880
				Filing Date (Int'l)	April 11, 2003
				First Named Inventor	Jens Peter GØTZE
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	271212000200

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1.	US-6,117,644	09-12-2000	DeBold	
	2.	US-6,124,430	09-26-2000	Mischak et al.	
	3.	US-6,376,207	04-23-2002	Mischak et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	4.	EP-1 016 867	07-05-2000	Asada		
	5.	WO-00/35951	06-22-2000	Univ. of Leicester		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	6.	ADACHI et al., Am. J. Physiol. (1995) 268:H162-H169		
	7.	CAMPBELL et al., J. Cardiac Failure (2000) 6:130-139		
	8.	CLERICO et al., Clinical Chemistry (2000) 46:1529-1534		
	9.	CLERICO et al., J. Endocrinol. Invest. (1998) 21:170-179		
	10.	GOETZE et al., Clinical Chemistry (2002) 48:1035-1042		
	11.	HARRISON et al., Annals of Emergency Medicine (2002) 39:131-138		
	12.	HUGHES et al., Clinical Science (1999) 96:373-380		
	13.	HUNT et al., Biochem. Biophys. Res. Comm. (1995) 214:1175-1183		
	14.	HUNT et al., Clinical Endocrinology (1997) 47:287-296		
	15.	HUNT et al., Peptides (1997) 18:1475-1481		
	16.	International Search Report for PCT/DK03/00250, mailed on June 25, 2003, 3 pages		
	17.	KARL et al., Scand. J. Clin. Lab. Invest. (1999) 59(Suppl 230):177-181		
	18.	LI et al., J. Biol. Chem. (1995) 270:5723-5728		
	19.	MAIR et al., Clin. Chem. Lab. Med. (2001) 39:571-588		
	20.	MORRISON et al., J. Am. Coll. Cardiol. (2002) 39:202-209		
	21.	SAGNELLA, Ann. Clin. Biochem. (2001) 38:83-93		
	22.	SCHULTZ et al., Scand. J. Clin. Lab. Invest. (2001) 61:33-42		
	23.	SEIDLER et al., Biochem. Biophys. Res. Comm. (1999) 255:495-501		
	24.	SIPS, Chem. Phys. (1948) 16:490-495		
	25.	MAIR, Clin. Chem (2002) 48:977-978		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

sd- 249021